| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
118,506,000 |
| Market
Cap: |
432.55(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.65 - $8.35 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 7.7 |
| Insider 3/6 Months : 8.3 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Fate Therapeutics is a clinical-stage biopharmaceutical company focused on the development of programmed cellular immunotherapies for patients with cancer. Co. is developing cell therapy product candidate. Co.'s off-the-shelf, induced pluripotent stem cells (iPSC) derived cellular immunotherapy pipeline include: FT516, which is an off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master iPSC line engineered to express a high-affinity, non-cleavable CD16 Fc receptor; and FT596, which is an off-the-shelf chimeric antigen receptor NK cell cancer immunotherapy derived from a clonal engineered master iPSC line.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
44,630 |
44,630 |
471,648 |
| Total Buy Value |
$0 |
$166,024 |
$166,024 |
$2,724,191 |
| Total People Bought |
0 |
1 |
1 |
2 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
2,447 |
54,627 |
96,836 |
590,364 |
| Total Sell Value |
$19,013 |
$243,259 |
$380,390 |
$5,527,958 |
| Total People Sold |
1 |
4 |
6 |
14 |
| Total Sell Transactions |
1 |
8 |
14 |
36 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Rastetter William H |
Director |
– • – |
2013-10-04 |
4 |
B |
$6.00 |
$499,998 |
I/I |
83,333 |
83,333 |
2.1 |
- |
|
| Mendlein John |
Director |
– • – |
2013-10-04 |
4 |
B |
$6.00 |
$100,002 |
D/D |
16,667 |
156,774 |
2.39 |
- |
|
| Nelsen Robert |
Director |
– • • |
2013-10-04 |
4 |
B |
$6.00 |
$4,999,998 |
I/I |
833,333 |
2,473,188 |
2.25 |
- |
|
| Nelsen Robert |
Director |
– • • |
2013-10-04 |
4 |
A |
$6.00 |
$770,682 |
I/I |
128,447 |
1,639,855 |
|
- |
|
| Nelsen Robert |
Director |
– • • |
2013-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
1,511,408 |
1,511,408 |
|
- |
|
| Shoemaker Daniel D |
Chief Technology OfficerOffice |
• – – |
2013-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
34,615 |
|
- |
|
| Flynn Peter D |
See RemarksOfficer |
• – – |
2013-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,769 |
|
- |
|
| Mendlein John |
Director |
– • – |
2013-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
140,107 |
|
- |
|
| Wolchko J Scott |
See RemarksOfficer |
• – – |
2013-09-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
35,026 |
|
- |
|
| Rastetter William H |
Director |
– • – |
2013-09-30 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
118,360 |
|
- |
|
335 Records found
|
|
Page 14 of 14 |
|
|
0.05 (1.35%) 
